Comparative Pharmacology
Head-to-head clinical analysis: CLOTRIMAZOLE versus NATACYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOTRIMAZOLE versus NATACYN.
CLOTRIMAZOLE vs NATACYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol biosynthesis and increasing membrane permeability.
Natamycin is a polyene antifungal that binds to ergosterol in fungal cell membranes, increasing permeability and causing cell death.
Topical: Apply thin layer to affected area twice daily for 2-4 weeks. Oral troche: 10 mg troche dissolved slowly in mouth 5 times daily for 14 days. Vaginal: One 100 mg suppository intravaginally at bedtime for 7 days, or 200 mg suppository for 3 days, or 500 mg single dose.
One drop of 5% ophthalmic suspension into the conjunctival sac every 1-2 hours for 48 hours, then taper to one drop 4-6 times daily.
None Documented
None Documented
Clinical Note
moderateClotrimazole + Tranilast
"The risk or severity of adverse effects can be increased when Clotrimazole is combined with Tranilast."
Clinical Note
moderateClotrimazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Clotrimazole is combined with Tolfenamic acid."
Clinical Note
moderateClotrimazole + Nimesulide
"The risk or severity of adverse effects can be increased when Clotrimazole is combined with Nimesulide."
Clinical Note
moderateTerminal half-life is approximately 3-6 hours; due to rapid hepatic metabolism and extensive tissue distribution, clinical effects persist longer than plasma levels suggest.
Not well characterized due to minimal systemic absorption; estimated to be 2-3 hours in plasma if absorbed.
Primarily fecal (biliary) as unchanged drug and metabolites; minimal renal excretion (<1% unchanged).
Primarily fecal via biliary elimination; less than 5% renal excretion of absorbed dose.
Category A/B
Category C
Antifungal
Antifungal, Ophthalmic
Clotrimazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Clotrimazole is combined with Risedronic acid."